Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Has Average Price Target of $5.55 According to Brokerages

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have earned an average rating of “Hold” from the nine research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $5.55.

Several analysts have issued reports on MYGN shares. Wells Fargo & Company set a $4.50 target price on shares of Myriad Genetics in a research note on Tuesday, October 20th. TD Cowen increased their price objective on Myriad Genetics from $4.50 to $6.75 and gave the company a “hold” rating in a report on Thursday. UBS Group began coverage on shares of Myriad Genetics in a report on Wednesday, September 9th. They set a “neutral” rating and a $3.60 price target for the company. Zacks Research upgraded shares of Myriad Genetics from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 15th. Finally, Piper Sandler raised Myriad Genetics from an “underweight” rating to a “neutral” rating and set a $5.00 target price for the company in a research report on Tuesday, October 20th.

Myriad Genetics Stock Performance

Shares of NASDAQ:MYGN traded down $0.37 during trading on Friday, hitting $5.92. 2,562,310 shares of the company traded hands, compared to its average volume of 3,077,596. The stock has a market capitalization of $566.25 million, a price-to-earnings ratio of -4.35 and a beta of 1.62. The business’s fifty day moving average is $4.50 and its 200-day moving average is $4.62. The company has a quick ratio of 1.98, a current ratio of 2.21 and a debt-to-equity ratio of 0.40. Myriad Genetics has a one year low of $2.74 and a one year high of $8.09.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Wednesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.09. The firm had revenue of $202.70 million during the quarter, compared to analysts’ expectations of $191.33 million. Myriad Genetics had a negative net margin of 13.96% and a negative return on equity of 16.09%. As a group, equities analysts predict that Myriad Genetics will post -0.99 earnings per share for the current fiscal year.

Key Stories Impacting Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, above analysts’ $191.33 million estimate, and a loss of $0.11 per share—narrower than the expected $0.20 loss. The company also raised the midpoint of its FY2026 revenue outlook to a range of $780 million–$790 million. Article: Myriad Genetics Raises FY26 Revenue Outlook Midpoint
• Positive Sentiment: TD Cowen raised its price target to $6.75 from $4.50, while retaining a Hold rating; Leerink Partners raised its target to $8 from $5, with a Market Perform rating. Higher targets suggest improved expectations, though neither firm upgraded its rating. Article: TD Cowen price target
• Neutral Sentiment: Myriad agreed to sell its Prenatal Health business for $210 million. The proceeds could support the company’s finances and focus, but the divestiture also changes its revenue base; the outlook is presented following the sale. Article: Myriad outlines 2026 outlook following divestiture
• Negative Sentiment: The company said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential exposure of sensitive information or disruption creates uncertainty and could be contributing to investor concern. Article: Myriad reports cybersecurity incident

Institutional Investors Weigh In On Myriad Genetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC bought a new stake in shares of Myriad Genetics during the first quarter worth $562,500,000. BlackRock Inc. acquired a new stake in Myriad Genetics during the 2nd quarter worth approximately $62,184,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Myriad Genetics during the 2nd quarter worth approximately $8,039,000. Man Group plc bought a new position in Myriad Genetics in the second quarter valued at approximately $5,189,000. Finally, Bank of America Corp DE acquired a new stake in shares of Myriad Genetics during the second quarter worth $5,150,000. 99.02% of the stock is owned by institutional investors and hedge funds.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.